Retension Pharmaceuticals, Inc. (RTSN)

Retension Pharmaceuticals will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

Retension Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	-	1.77	0.98
Research & Development	-	5.11	1.3
Operating Expenses	-	6.88	2.28
Operating Income	-12.56	-6.88	-2.28
Interest Expense (Income)	-0.62	-0.58	-0.36
Other Expense (Income)	0	-	-0.02
Pretax Income	-11.94	-6.3	-1.91
Net Income	-11.94	-6.3	-1.91

Additional Metrics

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-11.89	-7.78	-1.76
Free Cash Flow Growth	-	-	-
EBITDA	-12.56	-6.88	-2.27
EBIT	-12.56	-6.88	-2.27